Silo Pharma closes private placement raising about $815,000

Silo Pharma, Inc. entered into securities purchase agreements on November 5, 2026 with a group of accredited investors for a private placement. The deal covered 136,005 shares of common stock at $1.50 per share along with pre-funded warrants to purchase up to an aggregate of 430,661 shares at $1.4999 per warrant.¹

The pre-funded warrants are immediately exercisable at a nominal exercise price of $0.0001 per share, though a holder cannot exercise any portion if it would push their ownership above 4.99% of outstanding common stock, a cap that can be raised to as much as 9.99% with at least 61 days' notice to the company.¹

Alongside the purchase agreements, Silo Pharma signed a registration rights agreement dated November 5, 2026. Under that agreement, the company agreed to file a registration statement covering resale of the shares and warrant shares within 30 days, and to use best efforts to have it declared effective within 60 days, or 90 days if the SEC conducts a full review.¹

The private placement closed on November 6, 2026, with net proceeds expected to be approximately $815,000 after fees and expenses, which the company plans to use for working capital and general corporate purposes.¹

The securities were not registered under the Securities Act of 1933 or state securities laws, and were issued under exemptions provided by Section 4(a)(2) of the Securities Act and Regulation D.¹

The filing was signed by Chief Executive Officer Eric Weisblum.